Arcturus Therapeutics (NASDAQ:ARCT) Lowered to Sell at ValuEngine

Arcturus Therapeutics (NASDAQ:ARCT) was downgraded by equities researchers at ValuEngine from a “hold” rating to a “sell” rating in a research note issued on Thursday, ValuEngine reports.

Several other research analysts also recently weighed in on the company. Zacks Investment Research upgraded Arcturus Therapeutics from a “hold” rating to a “buy” rating and set a $10.00 target price on the stock in a research note on Tuesday, July 16th. Chardan Capital set a $18.00 target price on Arcturus Therapeutics and gave the stock a “buy” rating in a research note on Thursday, June 20th. HC Wainwright began coverage on Arcturus Therapeutics in a research note on Friday, April 5th. They set a “buy” rating and a $15.00 target price on the stock. Finally, Brookline Capital Management restated a “buy” rating on shares of Arcturus Therapeutics in a research note on Wednesday, July 24th. One research analyst has rated the stock with a sell rating, six have issued a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $14.33.

ARCT stock traded down $2.03 on Thursday, hitting $11.58. 405,621 shares of the company’s stock were exchanged, compared to its average volume of 59,589. Arcturus Therapeutics has a 12-month low of $4.11 and a 12-month high of $15.50. The stock’s 50 day simple moving average is $9.62. The company has a current ratio of 2.51, a quick ratio of 2.51 and a debt-to-equity ratio of 2.43. The firm has a market capitalization of $181.29 million, a PE ratio of -5.36 and a beta of 2.30.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its earnings results on Monday, May 13th. The biotechnology company reported ($0.68) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.53) by ($0.15). Arcturus Therapeutics had a negative return on equity of 132.46% and a negative net margin of 124.59%. The business had revenue of $4.35 million for the quarter, compared to analysts’ expectations of $3.47 million. As a group, sell-side analysts forecast that Arcturus Therapeutics will post -2.19 earnings per share for the current year.

A number of institutional investors have recently bought and sold shares of the business. ARK Investment Management LLC grew its stake in Arcturus Therapeutics by 8.3% during the 2nd quarter. ARK Investment Management LLC now owns 1,004,368 shares of the biotechnology company’s stock valued at $9,481,000 after purchasing an additional 77,224 shares during the last quarter. Nikko Asset Management Americas Inc. grew its stake in Arcturus Therapeutics by 102.8% during the 2nd quarter. Nikko Asset Management Americas Inc. now owns 129,974 shares of the biotechnology company’s stock valued at $1,227,000 after purchasing an additional 65,875 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. purchased a new stake in Arcturus Therapeutics during the 2nd quarter valued at about $1,227,000. Finally, Creative Planning purchased a new stake in Arcturus Therapeutics during the 1st quarter valued at about $416,000. Institutional investors and hedge funds own 11.15% of the company’s stock.

About Arcturus Therapeutics

Arcturus Therapeutics Ltd., an RNA medicines company, focuses on treatment of liver and respiratory diseases. The company's pipeline of RNA therapeutics include programs pursuing rare diseases, hepatitis B, non-alcoholic steatohepatitis, cystic fibrosis, and vaccines. The company owns LUNAR lipid-mediated delivery and Unlocked Nucleomonomer Agent (UNA) technology, including UNA Oligomers, which are covered by its patent portfolio, including 152 patents and patent applications issued in the United States, Europe, Japan, China, and internationally.

Recommended Story: Range Trading

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Arcturus Therapeutics (NASDAQ:ARCT)

Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.